Diesel and crude spike higher on Israel attack, though no Iranian oil facilities impacted
Oil futures prices soared Friday on the back of Israel's attack on Iran, but there were no indications any oil-related facilities had been impacted by the multi-pronged offensive by the Israeli military.
'Non-nuclear energy infrastructure has not been expressly threatened by any party thus far,' S&P Global Commodity Insights (SPGCI) (NYSE: SPGI) said in a 'factbox' summary of key energy-related developments stemming from the Israeli attack.
Ultra low sulfur diesel (ULSD) on the CME commodity exchange settled at $2.3587/gallon, an increase of exactly 17 cts/g or 7.77%.Friday's ULSD settlement is the highest since February 27.
The one-day increase of 17 cts/g is the highest since Jan. 10. The last time ULSD increased as much as December 2022, when it rose more than 18 cts/g. But the gain that day was 5.97%; today's was 7.77%.
The higher ULSD levels followed increases in global crude markets, which at first tend to rise or fall more in percentage terms than products like gasoline or diesel in reaction to real or potential disruptions in oil supply or demand. But that did not occur Friday, with ULSD rising more than the two key crude benchmarks in percentage terms.
Brent, the global crude benchmark, rose $4.87/barrel on the CME, an increase of 7.02% to settle at $74.23/b. West Texas Intermediate, the U.S. crude benchmark, climbed $4.94/b to $72.98/b. That marked a percentage gain of 7.26%.What's at stake through any widening of the war to include Iranian capacity to produce crude was spelled out by SPGCI in its factbox. The SPGCI segment, which houses the legacy Platts business, said Iran produced about 3.25 million b/d of crude in May.
Of the countries in the OPEC+ group of oil exporters, only Saudi Arabia, Russia and Iraq produced more. The U.S. is the world's largest crude producer with output of about 13.24 million b/d, according to the latest report by the Energy Information Administration.
But since the Iranian Revolution in 1979 and the takeover by its Islamic leaders–and its breach with most other Arab oil producers–the nightmare scenario for oil consumers has always been that Iran would take steps to close the Strait of Hormuz, which is the entrance to the Persian Gulf. Some portion of oil exports from Saudi Arabia, Kuwait, the United Arab Emirates, Iraq and Iran all pass through the Strait of Hormuz.
But despite those fears that have now been in place for more than 45 years, a closure has never happened. Several analysts Friday said it was not likely to happen this time either.
The Strait of Hormuz is 'obviously the major concern,' Paul Sankey of independent research firm Sankey Research said in an interview with CNBC. But he added that if Iran took steps to close the passage, 'all hell will break loose. I'm sure Donald Trump is going to be at the forefront of that unleashing of hell.'
But Sankey was not fully downplaying the impact from the Israeli attacks. He said the 'speed of the move we've seen is actually as fast as we saw during the Russian invasion of Ukraine. '
'Recently the oil market hasn't been characterized by reacting to geopolitical risk as much as you would think,' he said. 'On this occasion, we're doing a Russia-Ukraine reaction. So you have to ask yourself, why is that?'
Sankey said if there is a loss of output from Iran, it will be difficult to turn to the U.S. Strategic Petroleum Reserve to fill the gap. Reserves were drawn down by the Biden administration to compensate for the loss–real and anticipated–of Russian oil following its invasion of Ukraine in 2022.The other option to fill any gap, Sankey said, is spare capacity in several Middle East countries; Saudi Arabia, Kuwait, the United Arab Emirates and Iraq. But the problem with that spare capacity is that much of it is behind the Strait of Hormuz. 'I think the market is pricing real fear about spare capacity,' Sankey said. 'That's why the move has been so aggressive.'
Richard Joswick, the head of near-term oil analysts at SPGCI, said 'the key is whether oil exports will be affected.'
He noted that when Iran and Israel went back and forth with attacks last year, oil prices did move higher at first. The higher levels didn't stick for long once it became clear that the attacks had no impact on supply.
But the SPGCI report also quoted J.P. Morgan analysts who said the 'worst case-scenario' of lost output would be a decline of Iranian supplies of 2.1 million b/d. That could spike the price of dated Brent–the physical benchmark that is drawn from the market for several different crudes–to $120 to $130/b.
Retail prices take time to react to moves big and small in futures prices, though wholesale prices will be expected to move on the same day to reflect higher futures prices.
Pilot Flying J makes its retail pump prices available through a downloadable spreadsheet. As of 2 p.m. Friday, there was no indication of a surge in retail diesel prices as a result of the Israeli attack; any increases were small and of an amount that would be considered part of the normal day-to-day fluctuation.
That lack of movement is not surprising given that the attack just happened. When disruptions to physical supplies occur, like with a hurricane or pipeline outage, price spikes can be more rapid. That has not happened yet.
Patrick DeHaan, the head of petroleum analysis at GasBuddy, which tracks retail prices, said in a post on X that diesel could rise between 10-30 cts/g over the next two weeks.
More articles by John Kingston
Onstage in Chicago, CHRW talks tech and staffing; RXO sees language order hitting capacity
Logistics GDP share rose in '24, not likely to drop: CSCMP report
Trump signs bill killing California ZEV-related waivers, state immediately files lawsuit
The post Diesel and crude spike higher on Israel attack, though no Iranian oil facilities impacted appeared first on FreightWaves.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Carney's first foreign policy test begins at G7 — amid Middle East crisis and Trump's trade war
Prime Minister Mark Carney will welcome leaders of the world's most powerful democratic countries Sunday for the start of a three-day meeting in the Rocky Mountains — a high-stakes summit that longtime G7 observers say could be one of the most consequential in years. Carney's priorities for this gathering in Kananaskis, Alta., reflect the challenges of our time: war and peace, energy security with a focus on critical minerals and artificial intelligence and "securing the partnerships of the future," according to the Prime Minister's Office. This will include talk about U.S. President Donald Trump's aggressive trade actions against Canada and other G7 countries. And as parts of Western Canada go up in flames, Carney has also put wildfires on the agenda. The leaders will discuss bolstering joint responses to climate disasters and some sort of "wildfire charter" is expected. Israel's strikes against Iranian nuclear facilities and military sites, which began Friday, could overshadow the discussions on the official agenda. The guest list for the summit, which includes India's Narendra Modi, has drawn some domestic criticism but Carney has argued that big global challenges should be addressed by the world's big players — even if there are some lingering tensions."It's a landmark summit because never before have these leaders had to confront so many strong, simultaneously interconnected crises," said John Kirton, director of the G7 Research Group at the University of Toronto. Kirton is pleased with the guest list Carney has assembled, saying there are more leaders of consequence coming to Kananaskis than perhaps any other such meeting in recent memory. In addition to the G7 members and India, Brazil, South Africa, United Arab Emirates, South Korea, Ukraine, Mexico and Australia — the secretaries general of the UN, NATO and EU along with the head of the World Bank will be there for at least part of the proceedings. When Trudeau hosted in 2018, Canada's guest list included leaders from "overwhelmingly little countries" with a focus on those facing endangered by rising shorelines like Jamaica, the Marshall Islands and the Seychelles, Kirton said. "Carney's list — it's a great one," Kirton told CBC News. "If you really want to lead the world, and not just the G7 part of the world, then you want the next tier of the biggest leaders there at the table." Leaders will begin to arrive Sunday and then be ferried by helicopter to the summit site. Monday's session will be broadly focused on the economy and "economic peace," and then security matters, government officials said in a background briefing. The second day will be when the non-G7 leaders will be brought in. It's also when Ukraine will be a major focus. Carney personally invited Ukrainian President Volodymyr Zelenskyy to discuss a path forward for that war-torn country. Trump has been hostile to Ukraine at times as he pushes for a swift resolution to the war Russia started — but he has largely maintained U.S. military support and anti-Russia sanctions despite some of his tough talk. On trade and Ukraine, the summit's success will depend on what Trump does or does not do, said Fen Hampson, a professor of international relations and the co-chair of the expert group on Canada-U.S. relations at Carleton University. "Even when it comes to his tech bro buddies, things can go sideways pretty quickly," Hampson said. "That's really the big risk here — does the president arrive in a good mood willing to do business, or is he in a bad mood?" While he's not expecting Trump to drop all of his tariffs after a few days in the mountains, Hampson said a U.S. "commitment to work together in a positive way" and revisit trade actions could be spun as a win by Carney. A commitment from Trump to stay the course in Ukraine would also be well-received by Carney and the Europeans in the room, Hampson said. To secure that sort of shift, Europe may commit to dropping policies that irritate Trump, including its digital services tax, while Canada could play up its newfound commitment to a stronger military and more defence spending, longtime U.S. demands, Hampson said. But depending on Trump to play nice is a risky proposition, he said. "Carney is more than just the head waiter at this meeting," Hampson said. "This is going to be a real test of his own negotiating skills." Increasing tensions in the Middle East after Israel launched airstrikes in Iran will further test Carney. Iran fired dozens of missiles toward Israel hours later. "With Israel's attack on Iran, the Israeli-Palestinian conflict and Iran-Israel dynamics have to be at least informally on the agenda," University of Ottawa political science professor Thomas Juneau said. "It makes Prime Minister Carney's job way more complicated than it already was." No joint communique Unlike at past G7 summits, Canada is not planning to get all leaders to agree to a joint communique — a sometimes unwieldy list of priorities and accomplishments that all countries agree to sign. Instead, Canada has been working with the other countries ahead of time to secure leaders' approval on a series of short, joint statements focused on concrete actions and outcomes in key areas, a senior government official said ahead of the summit. This strategy could be interpreted as a way to avoid what befell the 2018 G7 meeting Canada hosted in Charlevoix, Que. Trump did not want to sign on to a series of climate change-focused measures — something former prime minister Justin Trudeau made a priority at those talks despite Trump's well-known hostility to environmentalism. The president ultimately agreed to the joint communique while withholding U.S. support for some green measures — but then torpedoed G7 unity entirely in a series of post-summit tweets, saying he was offended by what Trudeau said at a closing news conference. Rather than squabble over policy measures Trump will never support, Carney is focused on getting G7 leaders to coalesce around things that have a reasonable chance of garnering a consensus, a senior government official said. The government is framing this agenda as a more streamlined, focused document than the last one. Trudeau, by comparison, tried to get G7 support for 28 areas of agreement in Charlevoix. Trump may be the sticking point on trade and Ukraine, but Kirton said Carney's program suggests Canada is setting up this meeting to be a success on other issues. "If you're going to hit home runs, you really need the U.S. to go along with you. On many of Mark Carney's priorities, it's easy to see Donald Trump agreeing," he said, referring to defence spending, AI and a move to crack down on deadly drugs like fentanyl. "Carney has said he wants Canada to be a global leader. This is the way to make that happen — if he can pull it all together on the spot."
CNBC
an hour ago
- CNBC
Boeing Dreamliner crash, military escalations darken mood at Paris Air Show
Kelly Ortberg's first Paris Air Show as Boeing CEO was set to be relatively upbeat. Under his leadership that began in August, the company has made strides in ramping up production of its bestselling 737 Max jets, increasing cash-generating deliveries of new planes, and indicating that it's turning a corner from a series of manufacturing and safety crises and years of lost ground to rival Airbus. Shares are up more than 13% this year, outpacing the S&P 500. But after an Air India flight crashed on Thursday, marking the first fatal air disaster of a Boeing Dreamliner, Ortberg canceled plans to go to the massive air show that begins on Sunday. The trade event is a big draw for the industry and is held every other year, alternating with the Farnborough Air Show in the U.K. Boeing, Airbus and other aerospace giants host champagne-flowing parties, hold flashy deal-signing ceremonies with executives flanked by model planes, and show off their new aircraft with extreme maneuvers for spectators below. "As our industry prepares to start the Paris Air Show, Stephanie and I have both canceled plans to attend so we can be with our team, and focus on our customer and the investigation," Ortberg said in a note to employees late Thursday, referring to Boeing Commercial Airplanes CEO Stephanie Pope. All but one of the 242 people aboard Air India Flight 171 were killed when the more than 11-year-old Boeing 787-8 Dreamliner that was headed for London on a sweltering day crashed into a medical student dining hall seconds after takeoff from Ahmedabad in western India. The sole survivor was an India-born British national in seat 11A. The cause of the crash is unknown and will take weeks or months to determine. Questions focus on how the plane so quickly and evenly lost altitude, appearing to glide into a fireball crash. Cockpit voice and data recorders, known as "black boxes," will provide key information. "It is important that we do not speculate about the accident and let the investigators do their work," Ortberg wrote. The plane's engine maker, GE Aerospace, said it will postpone an investor day scheduled for Tuesday. The crash isn't the only outside factor changing the gathering in Paris. Shortly before the Paris Air Show was set to begin, Israel launched overnight missile strikes on Iran. Hours later, Iran launched drones toward Israeli territory. Airlines canceled flights, with jets in the air diverting or returning to their destinations, while hundreds of others skirted the airspace. The escalating tensions will make military budgets and spending an even bigger focus for the air show, but they also raise concerns about how conflicts and geopolitical tensions could impact demand for commercial air travel. Despite the crash and other external concerns, Boeing, Airbus and Embraer are expected to lock in hundreds of airplane orders. Wait times for popular new aircraft models already stretch into the next decade with demand still strong. Boeing forecast on Saturday that the world will need 43,600 commercial airplanes over the next two decades, with emerging markets driving growth. It expects those markets will account for more than half of the world's fleet in 2044, up from a 40% share last year. Some of the order signings could come from previously undisclosed customers, though there are many new orders on the line, aviation analysts say. Ongoing issues, such as a lack of trained workers, have delayed deliveries of new planes, while on-again, off-again tariffs have raised concerns about more expensive aircraft and components. Pricing has also firmed up. A new Airbus A321neo was going for $65 million as of the end of April, up from $58 million at the start of 2023, while a new Boeing 737 Max 8 cost about $55.5 million in April, compared with $50.25 million in early 2023, according to Ishka an aviation data and advisory firm. With aircraft still in short supply, lease rates are also going up for older planes for airlines that prefer not to make multimillion-dollar aircraft purchases up front or that might need them for shorter time periods. A 12-year-old Boeing 737 costs $241,000 a month to rent as of the end of April, up nearly 42% from two years earlier, and an Airbus A320 of the same age was $239,000 a month, a 50% gain, according to IBA Insight, another aviation data firm. U.K.-based IBA predicted manufacturers could see between 700 and 800 commercial aircraft orders during the Paris show, a tally that includes firm orders, options, and looser commitments like purchase intention letters and memoranda of understanding. Customers could include Ethiopian Airlines and Polish carrier Lot, as well as Vietnam Airlines, AirAsia, Royal Air Maroc, Etihad and Saudi carrier Riyadh, said Ishka. "A large deal from China is inevitable sometime, for replacement if not growth reasons," Ishka said in a note last week. Air India, which Ishka had previously listed as a potential customer, was no longer expected to buy new planes given last week's tragedy. Airplane customers are going bigger as international travel continues to bring in money. "It used to be all about single-aisle orders," said Richard Aboulafia, managing director at aerospace consulting firm AeroDynamic Advisory. Now, "everyone is booking these monster twin-aisle orders for international traffic." He said major international airlines like Turkish Airlines, Gulf carriers and others have expanded in recent years, competing for more global travelers, "slicing the pizza into smaller pieces." Since orders are placed years in advance, Aboulafia said he doesn't expect a big impact on demand because of the crash, though some might be held back during the show. "It's a terrible tragedy. It doesn't make anyone's lives easier," he said. "I just don't think given what we know now it has anything to do with the design or the build of the airplane. It sure doesn't look like it."
Business Wire
an hour ago
- Business Wire
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
VENLO, Netherlands & WILMINGTON, Del.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers, including Incyte's monoclonal antibody INCA033989, targeting mutant calreticulin (mutCALR), which is being developed in myelofibrosis (MF) and essential thrombocythemia (ET). Under the terms of the Master Collaboration Agreement with Incyte, QIAGEN will develop a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies. The panel will be validated using the next-generation sequencing (NGS) technology and the Illumina NextSeq 550Dx platform as part of QIAGEN's partnership with Illumina (NASDAQ: ILMN) to leverage its NGS diagnostic platforms for patient testing by laboratories worldwide. QIAGEN will support regulatory submission processes and market access activities across the United States, European Union and Asia-Pacific regions. Myeloproliferative neoplasms are a group of diseases representing about 40% of hematological malignancies, characterized by chronic accumulation of different mature blood cell types in blood. Identifying genomic aberrations in clinically relevant biomarkers like CALR are shown to be key, especially in MPNs. Incyte is at the forefront of developing novel therapies, including INCA033989 for patients with mutCALR ET or MF, that target only malignant cells, sparing normal cells. The use of companion diagnostics helps guide clinicians in making treatment decisions that can lead to better patient outcomes. 'Following our presentation of positive, late-breaking data from our first-in-class mutCALR-targeted antibody at EHA, we are excited to announce this partnership with QIAGEN, which will facilitate CALR testing for patients with MPNs on a global basis. The development of companion diagnostics for mutCALR, coupled with the potential for new medicines to selectively target disease-initiating cells, is a critical step toward changing the course of disease in patients with ET and MF,' said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. 'As a partner, QIAGEN has the proven expertise in companion diagnostics development and approvals needed to support our ongoing work and commitment to transforming the treatment of patients with CALR-mutant MPNs.' 'Together with Incyte we are building a multimodal companion diagnostic using a powerful technology like next-generation sequencing to facilitate highly accurate testing for several blood cancer genes at once,' said Jonathan Arnold, Vice President and Head of Partnering for Precision Diagnostics at QIAGEN. 'This new partnership strengthens our role in offering companion diagnostics for the growing number of biomarkers being discovered in onco-hematology and maximizing the clinical utility of the diagnostic for payor and patient benefit, thus supporting the work of innovative, science-driven companies like Incyte to improve patient outcomes.' About Mutations in Calreticulin (mutCALR) Calreticulin (CALR) is a protein involved in the regulation of cellular calcium levels and normal protein production. Somatic, or non-inherited, DNA mutations in the CALR gene (mutCALR) can result in abnormal protein function and lead to the development of myeloproliferative neoplasms (MPNs), i a closely related group of clonal blood cancers in which the bone marrow functions abnormally, overproducing blood cells. ii,iii Among the two types of MPNs, essential thrombocythemia (ET) and myelofibrosis (MF), mutCALR drives 25-35% of all cases. i,ii About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit QIAGEN is a pioneer in precision medicine and the leader in collaborating with pharmaceutical and biotechnology companies to develop companion diagnostics, having more than 30 master collaboration agreements with global pharmaceutical and biotechnology companies to develop and commercialize diagnostic tests. QIAGEN's offering to these companies encompasses technologies ranging from polymerase chain reaction (PCR), near-patient testing and digital PCR (dPCR) to next-generation sequencing (NGS), and sample types from liquid biopsy to tissue. It also spans disease areas from cancer to non-oncology diseases such as neurodegenerative, inflammatory, and metabolic diseases – including 16 FDA-approved PCR-based companion diagnostics. For more information about QIAGEN's efforts in precision medicine please visit About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For additional information on Incyte, please visit or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube. QIAGEN Forward-Looking Statement Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the 'Risk Factors' contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission. Incyte Forward-Looking Statements Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the potential for Incyte's mut-CALR targeted antibody (INCA033989) to provide a potential treatment option for patients with ET or MF, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on Incyte's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA, EMA, and other regulatory authorities; the efficacy or safety of Incyte and its partners' products; the acceptance of Incyte and its partners' products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-Q for the quarter ended March 31, 2025. Incyte disclaims any intent or obligation to update these forward-looking statements. Source: QIAGEN N.V. Category: Precision Medicine
